LXEO Dividend: Lexeo Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

LXEO Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	0	1	0
Revenue Growth (YoY)	--	--	--	-100%	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	47	32	15	12	7	0
Research & Development	65	--	53	49	45	4
Operating Expenses	113	106	68	61	52	5
Other Non Operating Income (Expenses)	0	8	0	0	0	0
Pretax Income	-104	-98	-66	-59	-50	-5
Income Tax Expense	--	--	0	0	0	0
Net Income	-104	-98	-66	-59	-50	-5
Net Income Growth	21%	48%	12%	18%	900%	--
Shares Outstanding (Diluted)	60.98	32	24.66	24.67	24.67	24.67
Shares Change (YoY)	84%	30%	0%	0%	0%	--
EPS (Diluted)	-1.72	-3.06	-2.69	-2.4	-2.05	-0.21
EPS Growth	-34%	14%	12%	17%	876%	--
Free Cash Flow	-107	-81	-59	-55	-44	-3
Free Cash Flow Per Share	-1.75	-2.53	-2.39	-2.22	-1.78	-0.12
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	-5,000%	0%
Profit Margin	0%	0%	0%	0%	-5,000%	0%
Free Cash Flow Margin	0%	0%	0%	0%	-4,400%	0%
EBITDA	-113	-106	-68	-60	-50	-4
EBITDA Margin	0%	0%	0%	0%	-5,000%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-113	-106	-68	-60	-50	-4
EBIT Margin	0%	0%	0%	0%	-5,000%	0%
Effective Tax Rate	--	--	0%	0%	0%	0%